R&D and GxP regulated environments have different risk profiles, compliance requirements, and testing constraints. Learn why a single unified pen test scope fails both and how to run dual-scope engagements efficiently.

Section 524B made medical device cybersecurity a legal requirement, not a guideline. Learn what the FDA expects from your pen test scope, evidence package, and postmarket vulnerability management process.

Completing a pen test isn't enough for CMMC. Learn what C3PAO assessors actually look for in your evidence package and how to align your report, scope, POA&M, and remediation docs to specific practice statements.